Mobia Medical (MOBI) adds Dr. Myriam Curet as independent board member
Rhea-AI Filing Summary
Mobia Medical, Inc. expanded its Board of Directors from seven to eight members effective July 30, 2026 and appointed Myriam J. Curet, M.D. as a new Class II director. Her term runs until the company’s 2028 annual meeting of stockholders, or until a successor is elected and qualified.
The Board determined that Dr. Curet qualifies as an independent director under SEC and Nasdaq rules. She is not yet assigned to any Board committee and will receive compensation under Mobia’s non-employee director compensation program, along with the company’s standard indemnification agreement. The company states there are no related-party transactions with Dr. Curet requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board size: 8 directors
Director term end: 2028 annual meeting of stockholders
Intuitive Surgical CMO tenure: November 2017 to March 2026
+3 more
6 metrics
Board size
8 directors
Board increased from seven to eight members effective July 30, 2026
Director term end
2028 annual meeting of stockholders
Term of Class II director Myriam J. Curet, M.D.
Intuitive Surgical CMO tenure
November 2017 to March 2026
Period Dr. Curet served as EVP and Chief Medical Officer of Intuitive Surgical, Inc.
Stanford Clinical Professor role
since 2015
Service as Clinical Professor of Surgery at Stanford University School of Medicine
Stereotaxis board service
since July 2021
Dr. Curet’s role on Stereotaxis, Inc. board of directors
Inspire Medical Systems board service
since December 2023
Dr. Curet’s role on Inspire Medical Systems, Inc. board of directors
Key Terms
independent director, non-employee director compensation program, indemnification agreement, Item 404(a) of Regulation S-K, +1 more
5 terms
independent director regulatory
"the Board determined that Dr. Curet qualifies as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
non-employee director compensation program regulatory
"receive compensation as a non-employee director in accordance with Mobia’s"
indemnification agreement regulatory
"Mobia expects to enter into its standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Item 404(a) of Regulation S-K regulatory
"There are no transactions between Dr. Curet and Mobia that would be reported"
Class II director regulatory
"Dr. Curet was appointed as a Class II director, with a term expiring"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Mobia Medical (MOBI) announce regarding its Board of Directors?
Mobia Medical expanded its Board from seven to eight directors and appointed Myriam J. Curet, M.D. as a new Class II director, with a term running to the 2028 annual meeting or until a successor is elected and qualified.
Is Dr. Myriam Curet considered an independent director at Mobia Medical (MOBI)?
Yes. Mobia’s Board determined that Dr. Curet qualifies as an independent director under applicable SEC rules and Nasdaq listing standards, meaning she meets regulatory criteria for independence from management and the company.
What is the term of Dr. Curet’s directorship at Mobia Medical (MOBI)?
Dr. Curet was appointed as a Class II director with a term expiring at Mobia Medical’s 2028 annual meeting of stockholders, or until her successor is duly elected and qualified, or her earlier death, resignation, or removal.
Will Dr. Curet serve on any Mobia Medical (MOBI) board committees?
The company states that Dr. Curet has not been appointed to any Board committee at this time. Her committee assignments, if any, would be determined later by Mobia Medical’s Board of Directors.
How will Mobia Medical (MOBI) compensate Dr. Curet as a director?
Dr. Curet will receive compensation as a non-employee director under Mobia Medical’s existing non-employee director compensation program, and the company expects to enter into its standard indemnification agreement with her.